Cadrenal Therapeutics retains Tungsten Advisors for strategic review
Compartilhar
Cadrenal Therapeutics (NASDAQ:CVKD) initiated a formal strategic review process and retained Tungsten Advisors as its exclusive financial advisor.
Cadrenal Therapeutics (NASDAQ:CVKD) initiated a formal strategic review process and retained Tungsten Advisors as its exclusive financial advisor.
Cadrenal Therapeutics (NASDAQ:CVKD) reported a positive outcome from a July 28, 2026 FDA Type D meeting regarding the planned Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.
Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.
